Drizalma Sprinkle Capsule, Delayed Release
Product Images NDC 47335-618

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Drizalma Sprinkle (NDC 47335-618). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

60 mg (B41423b8 Dfec 4d79 Ba3c E43a87803d85 00)

FDA Label Image

40 mg (B41423b8 Dfec 4d79 Ba3c E43a87803d85 01)

FDA Label Image

30 mg (B41423b8 Dfec 4d79 Ba3c E43a87803d85 02)

FDA Label Image

Spl-structure (Image 01)

FDA Label Image

Spl-figure 1 (Image 02)

FDA Label Image

Spl-figure 2 (Image 03)

This is a graph showing the proportion of patients with relapse over time from randomization to relapse (in days) in a clinical trial comparing a placebo group to a group taking the drug duloxetine. The y-axis shows the percentage of patients with relapse while the x-axis shows the time in days.*

FDA Label Image

Figure 3 (Image 04)

FDA Label Image

Figure 4 (Image 05)

FDA Label Image

Figure (Image 06)

This is a graph that shows the percentage of patients who improved while taking Duloxetine 60/120mg once daily compared to a placebo. The x-axis shows the percent improvement in pain from baseline (BOCF) and the y-axis shows the percentage of patients who improved. The graph shows that a higher percentage of patients improved when taking Duloxetine compared to the placebo.*

FDA Label Image

Figure (Image 07)

This appears to be a chart that displays the percentage of patients who improved with a medication called DULOXETINE 60 mg once daily compared to a placebo. The chart also shows the percent improvement in pain from baseline.*

FDA Label Image

Figure (Image 08)

This text provides a chart displaying the percentage of patients improved with the use of Duloxetine 60/120 mg compared to a placebo. The chart also displays the percent improvement in pain from baseline.*

FDA Label Image

Spl Drizalma 20mg Label

FDA Label Image

Spl Drizalma Figure5

FDA Label Image

Spl Drizalma Figure6

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.